Teva Q3 Revenue $4.4B, Beats $4.24B Estimate; Adjusted EPS $0.86 vs $0.72

The Q3 beat on both revenue and adjusted EPS suggests Teva's core generic and specialty business is holding up better than consensus expected, a relevant read-across for healthcare-linked RWA and tokenized-equity narratives that lean on pharma cash flows. The gap between adjusted EPS and revenue outperformance points to margin or cost dynamics rather than pure top-line strength, though the item gives no detail on drivers. Whether the beat reflects durable operating leverage or one-off items is the open question, and the absence of guidance or segment breakdown here leaves that unresolved.